Figure 5.
Effect of abatacept on IgG, RF, and anti-SS-A antibody in SS. Effects of abatacept treatment on (A) serum IgG level (n = 31), (B) serum RF level (n = 30 patients), (C) titer of anti-SS-A antibody (n = 20 patients). Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), N.S; not significant vs baseline, Wilcoxon signed-rank test. ABT; abatacept.